Krystal Biotech KRYS - 옵션 체인 | ADVFN

다우존스 지수

브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

등록

Krystal Biotech Inc (KRYS)

181.10

-5.79

(-3.10%)

종가: 26 2월 6:00AM

181.10

0.13

( 0.07% )

시간외 거래: 9:33AM

KRYS 실시간 옵션 플로우

콜

행사 가격	매수가	매도가	최근 가격	중간 가격	가격 변동	가격 변동 %	거래량	미결제 약정	최근 거래
130.00	50.60	53.90	0.00	52.25	0.00	0.00 %	0	0	-
135.00	50.50	54.80	0.00	52.65	0.00	0.00 %	0	0	-
140.00	45.50	49.90	0.00	47.70	0.00	0.00 %	0	0	-
145.00	40.50	45.40	0.00	42.95	0.00	0.00 %	0	0	-
150.00	36.00	40.20	36.00	38.10	0.00	0.00 %	0	0	-
155.00	27.10	29.90	33.58	28.50	0.00	0.00 %	0	0	-
160.00	26.50	31.40	28.70	28.95	0.00	0.00 %	0	203	-
165.00	22.00	26.50	22.05	24.25	0.00	0.00 %	0	61	-
170.00	18.00	22.40	20.00	20.20	0.00	0.00 %	0	310	-
175.00	11.00	14.50	16.00	12.75	0.00	0.00 %	0	1,013	-
180.00	8.00	11.50	10.62	9.75	-2.78	-20.75 %	1	101	26/02/2025
185.00	7.50	12.00	10.70	9.75	0.00	0.00 %	0	53	-
190.00	5.80	9.30	7.50	7.55	0.00	0.00 %	0	72	-
195.00	1.65	5.90	2.40	3.775	0.00	0.00 %	0	2	-
200.00	0.50	4.70	2.20	2.60	-1.70	-43.59 %	1	21	26/02/2025
210.00	1.30	2.80	0.00	2.05	0.00	0.00 %	0	0	-
220.00	0.10	2.55	1.50	1.325	0.00	0.00 %	0	1	-

개인 투자자를 위한 전문가급 도구.

풋

행사 가격	매수가	매도가	최근 가격	중간 가격	가격 변동	가격 변동 %	거래량	미결제 약정	최근 거래
130.00	0.00	2.25	0.00	0.00	0.00	0.00 %	0	0	-
135.00	0.00	2.30	0.00	0.00	0.00	0.00 %	0	0	-
140.00	1.00	2.40	1.00	1.70	0.00	0.00 %	0	2	-
145.00	10.42	2.90	10.42	6.66	0.00	0.00 %	0	1	-
150.00	0.35	3.00	10.90	1.675	0.00	0.00 %	0	221	-
155.00	0.15	3.60	3.05	1.875	0.00	0.00 %	0	5	-
160.00	0.45	2.90	2.50	1.675	0.00	0.00 %	0	200	-
165.00	1.10	2.50	0.00	1.80	0.00	0.00 %	0	0	-
170.00	1.95	6.10	8.00	4.025	0.00	0.00 %	0	2	-
175.00	2.70	5.10	4.00	3.90	0.00	0.00 %	0	35	-
180.00	3.00	6.70	5.25	4.85	0.00	0.00 %	0	4	-
185.00	8.30	12.10	8.10	10.20	0.95	13.29 %	1	4	25/02/2025
190.00	11.30	15.10	9.00	13.20	0.00	0.00 %	0	1	-
195.00	14.90	18.50	0.00	16.70	0.00	0.00 %	0	0	-
200.00	18.80	22.30	0.00	20.55	0.00	0.00 %	0	0	-
210.00	27.60	30.70	0.00	29.15	0.00	0.00 %	0	0	-
220.00	31.50	35.50	0.00	33.50	0.00	0.00 %	0	0	-

가장 활성
% 상승자
% 패자

기호	가격	볼륨
ONVOOrganovo Holdings Inc	US$ 1.2502 (238.81%)	380.81M
RETOReTo Eco Solutions Inc	US$ 1.065 (80.51%)	78.62M
VEROVenus Concept Inc	US$ 0.5402 (76.54%)	15.53M
SLXNSilexion Therapeutics Corporation	US$ 1.23 (64.00%)	87.3M
WAFUWah Fu Education Group Ltd	US$ 2.825 (57.82%)	124.94M
YYAIConnexa Sports Technologies Inc	US$ 0.681 (-46.38%)	6.08M
SNDKSanDisk Corporation	US$ 48.06 (-36.91%)	8.09M
RNAZTransCode Therapeutics Inc	US$ 4.34 (-35.99%)	607.51k
ACONAclarion Inc	US$ 3.25 (-30.26%)	414.94k
BTDRBitdeer Technologies Group	US$ 9.255 (-29.35%)	16.63M
ONVOOrganovo Holdings Inc	US$ 1.2502 (238.81%)	380.81M
NVDANVIDIA Corporation	US$ 126.63 (-2.80%)	267.63M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 14.41 (-16.85%)	166.15M
SMCISuper Micro Computer Inc	US$ 45.54 (-11.76%)	144.12M
TSLATesla Inc	US$ 302.80 (-8.39%)	132.68M

Monksdream

Monksdream 4 월 전

KRYS. Under $200

Monksdream

Monksdream 7 월 전

KRYS new 52 week high

Monksdream

Monksdream 10 월 전

KRYS 10Q due 5/6

Monksdream

Monksdream 11 월 전

Monksdream

Monksdream 12 월 전

KRYS new 52 week high

Monksdream

Monksdream 2 년 전

From Cathie Wood
A Novel Gene Therapy Promises Relief For A Rare Genetic Skin Disorder
ARK Invest_Illustration_Pierce Jamieson_Final_Circle 400 px By Pierce Jamieson | @PierceARK
Research Associate
Recently, the US Food and Drug Administration (FDA) approved Krysta Biotech’s (KRYS) groundbreaking advance1 in gene therapy, Vyjuvek, to treat wounds in patients suffering from dystrophic epidermolysis bullosa (DEB), a rare and serious genetic skin disorder caused by mutations in the collagen Type VII alpha 1 chain (COL7A1) gene. As the first FDA-approved gene therapy for DEB, Vyjuvek is a significant breakthrough.

Vyjuvek uses a genetically modified HSV-1 to deliver normal copies of the COL7A1 gene to wounds, restoring the integrity of the skin with fibrils that hold skin layers together. Treated with Vyjuvek, 65% of wounds closed completely.

wiredawg

wiredawg 3 년 전

Moving nicely today...

wiredawg

wiredawg 3 년 전

Looking at the few posts here there seems to be no real commitment here...any thoughts on KRYS? Hype or something brewing?

wiredawg

wiredawg 3 년 전

In the last 3 months, 5 ranked analysts set 12-month price targets for KRYS. The average price target among the analysts is $125.00. Analysts compare their price target to the current market price of the stock to determine how much potential upside or downside movement there could be in the stock price. High $140 Low $111

wiredawg

wiredawg 3 년 전

30 Nov Tues releases this PR during evening after market close:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-pricing-200-million-public-offering

wiredawg

wiredawg 3 년 전

29 Nov Mon after market closes release this PR:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-proposed-200-million-public-offering

wiredawg

wiredawg 3 년 전

29 Nov Monday pre-market news release, great move pre-market approx 7am and so far holding fairly well:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-topline-results-gem-3-pivotal

wiredawg

wiredawg 3 년 전

This caught my eye on Monday, the huge move off the PR...I'm guessing here saw the same. Any real thoughts regarding the company and this PR. I have not gotten a chance to dig into it. Hoping to have somm DD done over the weekend.

wiredawg

wiredawg 3 년 전

Holding well so far, why the pretty hard drop?

wiredawg

wiredawg 3 년 전

Why are you surprised? Serious question, not being impudent...

rynlrt

rynlrt 3 년 전

200 million dollar offering. Won't be surprised to see it drop pretty hard when the market opens

Fofo812

Fofo812 3 년 전

Surprised it held up this long

crudeoil24

crudeoil24 3 년 전

Large tutes holdings. Some taking huge gains before years end.

rynlrt

rynlrt 3 년 전

Not sure this kind of gain is sustainable. May see a big pullback

Fofo812

Fofo812 3 년 전

crudeoil24

crudeoil24 3 년 전

Krystal Biotech shares are trading higher after the company announced its GEM-3 trial met its primary endpoint.

Trophy

Trophy 5 년 전

Krystal Biotech

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관